In a study of STZ-induced diabetes mice, CCL3 and CCL9 levels are increased in the lumbar spinal cord, while neutralizing antibodies against CCL3 or CCL9 delay neuropathic pain symptoms following STZ administration, and the application of CCR1 antagonist also alleviates pain-related behavior in diabetic neuropathy (Rojewska et al., 2018). The gene discussed is CCL3; the disease is diabetic neuropathy.